The Latest Cardiac and Vascular News
HANOVER, Germany–(BUSINESS WIRE)–Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the dosing of the first patient in their multicenter Phase 2 trial assessing efficacy and safety of CDR132L in 280 patients with reduced left ventricular ejection fraction after myocardial infarction […]
Further milestone for company as it fulfills its mission to detect cardiac disease earlier in patients BRISBANE, Calif., July 19, 2022 /PRNewswire/ — Caption Health, the leader in using AI and services to improve heart ultrasound access, today announced that it has received a CE Mark for its Caption AI™ technology platform. This […]
SAN FRANCISCO, July 18, 2022 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced that Dave Vort, the Company’s Chief Commercial Officer, has resigned effective July 25, 2022. To support continued growth and ongoing implementation of iRhythm’s commercial strategy, […]
Company is constructing a new commercial manufacturing facility and anticipates expanding its workforce to support the launch of its comprehensive patient management platform for heart failure LISLE, Ill., July 19, 2022 /PRNewswire/ — Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced plans […]
MARLBOROUGH, Mass., July 19, 2022 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatments for atrial fibrillation (Afib), today announced several milestones toward the development of a next generation pulse field ablation (PFA) technology for treatment of AFib, including the formation of a clinical advisory board, filing of […]
DSR (Direct Sodium Removal) heart failure drug development: Completed enrollment in SAHARA Ii with first-generation DSR product (“DSR 1.0”) – extending study with second-generation DSR product (“DSR 2.0”) to support US INDii filing by year end Proof-of-concept delivered in diuretic-resistant heart failure patients with dramatic and durable improvements in validated clinical measures Heart failure disease-modifying profile – safe, rapid and effective decongestion with no congestion-related heart failure re-hospitalizations observed […]
Highly experienced US medtech leader brings more than 40 years’ experience Ghent, Belgium – 19 July 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, today announces the appointment of Doug […]
Expanded Access for 125,000 American Lives for Highly Accurate, Novel Blood Tests KIRKLAND, Wash.–(BUSINESS WIRE)–Prevencio, Inc. today announces that Atlas Genomics, Prevencio’s performing laboratory for its Artificial Intelligence (AI)-driven cardiac HART blood tests, has entered into a preferred provider agreement with Alivio Health to provide expanded access for Prevencio’s HART tests. The coverage includes […]
Partnership Reinforces USHV’s Strong Position in Houston and Supports Long-Term Goals for National Footprint Expansion NASHVILLE, Tenn.–(BUSINESS WIRE)–US Heart & Vascular (“USHV”), the leading national provider of support services to cardiovascular physician practices, announced today that it has signed a definitive agreement regarding its partnership with Willowbrook Cardiovascular Associates (“Willowbrook”), […]
CARDINAL-HF is the first Phase 2 proof-of-concept trial of a PDE9 inhibitor in heart failure Large-scale trial builds upon encouraging data generated in Cardurion’s Phase 1b trial CARDINAL-HF will examine the effects of CRD-740, Cardurion’s PDE9 inhibitor, in both types of heart failure and in key subsets of these patients […]
